Looking forward, federal developments could shift states back toward coverage: the November 2025 announcement of most-favored-nation pricing and CMSs BALANCE model will likely make these drugs more affordable for state Medicaid programs, potentially improving short-term cost-effectiveness
Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE
reported that in a diet-dependent mouse model, adropin 34-76 suppressed cAMP-activated protein kinase A activity and reduced the phosphorylation of inositol triphosphate receptor and element-binding protein
Retatrutide is not it is an investigational compound in published research
Enhance with a bit of Emu Oil-S Lipid Replenisher (or Retinol in Squalane) to smooth this thick cream for easier application
Safety and side effects Well tolerated and the most commonly reported side effect is mild GI distress at higher doses